BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1041@pharmaconomics
DTSTAMP:20260707T050744Z
DTSTART;VALUE=DATE:20260831
DTEND;VALUE=DATE:20260901
SUMMARY:LGVN Phase 2 — laromestrocel (LOMECEL-B®)
DESCRIPTION:Phase 2 trial results for laromestrocel (LOMECEL-B®) in hypoplastic left heart syndrome (HLHS) are due Aug 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1721484/000121390026053902/ea028985301ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/1041
URL:https://www.pharmaconomics.com/e/1041
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:LGVN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR